BioCentury
ARTICLE | Company News

Medivir, Trek Therapeutics deal

August 22, 2016 7:00 AM UTC

Medivir granted Trek exclusive, worldwide rights outside of Taiwan and China, including Hong Kong and Macau, to develop and commercialize MIV-802. The pan-genotypic uridine nucleotide HCV NS5B polym...